[{"id":"ea90660c-49af-4b83-829a-76d449a7f624","acronym":"","url":"https://clinicaltrials.gov/study/NCT00281658","created_at":"2021-01-18T00:57:33.665Z","updated_at":"2024-07-02T16:35:55.790Z","phase":"Phase 3","brief_title":"Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2","source_id_and_acronym":"NCT00281658","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • PIK3CA • PTEN • KIT","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • PIK3CA mutation • PTEN mutation • PTEN-L","tags":["HER-2 • PIK3CA • PTEN • KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • PIK3CA mutation • PTEN mutation • PTEN-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • lapatinib"],"overall_status":"Completed","enrollment":" Enrollment 444","initiation":"Initiation: 01/02/2006","start_date":" 01/02/2006","primary_txt":" Primary completion: 06/18/2010","primary_completion_date":" 06/18/2010","study_txt":" Completion: 11/23/2021","study_completion_date":" 11/23/2021","last_update_posted":"2023-02-10"},{"id":"93b982fb-7c66-4921-b195-8eee74c88fbc","acronym":"LOTUS ","url":"https://clinicaltrials.gov/study/NCT02162719","created_at":"2021-01-17T17:26:40.920Z","updated_at":"2024-07-02T16:36:33.527Z","phase":"Phase 2","brief_title":"A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors","source_id_and_acronym":"NCT02162719 - LOTUS ","lead_sponsor":"Genentech, Inc.","biomarkers":" PIK3CA • PTEN • AKT1","pipe":" | ","alterations":" PTEN-L","tags":["PIK3CA • PTEN • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • ipatasertib (RG7440)"],"overall_status":"Completed","enrollment":" Enrollment 124","initiation":"Initiation: 08/19/2014","start_date":" 08/19/2014","primary_txt":" Primary completion: 06/07/2016","primary_completion_date":" 06/07/2016","study_txt":" Completion: 08/31/2019","study_completion_date":" 08/31/2019","last_update_posted":"2021-03-10"},{"id":"35735df2-86d0-400b-a043-bcc2da08da06","acronym":"FAIRLANE","url":"https://clinicaltrials.gov/study/NCT02301988","created_at":"2021-01-18T10:53:00.435Z","updated_at":"2024-07-02T16:37:05.982Z","phase":"Phase 2","brief_title":"A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer","source_id_and_acronym":"NCT02301988 - FAIRLANE","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • PTEN","pipe":" | ","alterations":" PTEN-L","tags":["HER-2 • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • ipatasertib (RG7440)"],"overall_status":"Completed","enrollment":" Enrollment 151","initiation":"Initiation: 02/17/2015","start_date":" 02/17/2015","primary_txt":" Primary completion: 08/02/2017","primary_completion_date":" 08/02/2017","study_txt":" Completion: 08/02/2017","study_completion_date":" 08/02/2017","last_update_posted":"2018-10-17"},{"id":"86016884-d6ee-490d-bf5d-5bac693c02a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01493843","created_at":"2021-01-18T06:15:28.162Z","updated_at":"2024-07-02T16:37:23.101Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01493843","lead_sponsor":"Genentech, Inc.","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA amplification • PTEN-L","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA amplification • PTEN-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • pictilisib (GDC-0941)"],"overall_status":"Completed","enrollment":" Enrollment 501","initiation":"Initiation: 01/20/2012","start_date":" 01/20/2012","primary_txt":" Primary completion: 03/30/2016","primary_completion_date":" 03/30/2016","study_txt":" Completion: 03/30/2016","study_completion_date":" 03/30/2016","last_update_posted":"2017-04-25"}]